Clinical Trial Update: Study of BLU-808 in Allergic Rhinoconjunctivitis [Phase 2]

View source ↗

Summary

A Phase 2 study of BLU-808 for allergic rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• BLU-808

Snippet

Sponsor: Blueprint Medicines Corporation | Conditions: Allergic Rhinoconjunctivitis | Phase 2 | Status: COMPLETED